MA
CRL icon

Mudita Advisors’s Charles River Laboratories CRL Stock Holding History

Mudita Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,607
Closed -$1.77M – 19
2024
Q4 		$1.77M Sell
9,607
-17,100
-64% -$3.29M 1% 16
2024
Q3 		$5.26M Sell
26,707
-7,893
-23% -$1.64M 2.88% 11
2024
Q2 		$7.15M Buy
34,600
+10,600
+44% +$2.4M 3.66% 9
2024
Q1 		$6.5M Buy
24,000
+3,000
+14% +$716K 3.87% 10
2023
Q4 		$4.96M Buy
21,000
+1,500
+8% +$295K 3.45% 11
2023
Q3 		$3.82M Buy
19,500
+4,500
+30% +$924K 2.79% 12
2023
Q2 		$3.15M Buy
+15,000
New +$2.98M 2.41% 15

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mudita Advisors's CRL Position: Q1 2025 in Review

Mudita Advisors sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 9,607 shares — an estimated $1.77M sold.

Mudita Advisors first reported a position in CRL in Q2 2023 and held it in 7 quarters. The position peaked at $7.15M in Q2 2024. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

  • Mudita Advisors reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
  • Mudita Advisors sold 9,607 Charles River Laboratories shares in Q1 2025, an estimated $1.77M.
  • Mudita Advisors first reported a position in Charles River Laboratories in Q2 2023 and held it in 7 quarters.
  • Mudita Advisors's Charles River Laboratories position peaked at $7.15M in Q2 2024.
  • 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Mudita Advisors's 13F filing for Q1 2025, filed 19 May 2025.